Loading...
•
Apr 01, 2022
Integer Q1 2022 Earnings Report
Integer Holdings Corporation reported first quarter 2022 results, with sales and profit consistent with expectations and 2022 outlook updated for Aran Biomedical acquisition.
Key Takeaways
Integer Holdings Corporation reported first quarter 2022 financial results consistent with expectations, with double-digit sales growth expected for the rest of the year, beginning in the second quarter, as well as gross margin improvement through the remainder of 2022. The 2022 outlook now includes the acquisitions of Oscor and Aran Biomedical, with projected sales growth of 11 to 13% and adjusted EBITDA growth of 12 to 17%, year-over-year.
Integer delivered first quarter 2022 financial results consistent with our expectations.
First quarter progress on direct labor staffing and supply chain position us well for growth.
Expect double-digit sales growth for the rest of the year, beginning in the second quarter, as well as gross margin improvement through the remainder of 2022.
Continue to execute our strategy to accelerate top-line growth by adding approximately $90 million of annualized sales at accretive growth rates from our two recent acquisitions.
Forward Guidance
2022 outlook updated for Aran Biomedical acquisition. Expected organic sales growth remains 5% to 7%.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...